Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $38.8152W HIGH $104.98
Volume
21.56 M
Value Traded
2.26 B
Short % Float
4.18%
+1.33%Week
+1.55%1 Month
+3.36%3 Month
+96.53%6 Month
-18.67%5 Year
+611.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
20.03 B
EPS (TTM)
-1.10
P/E Ratio
-
Ent. Value
21.60 B
Total Shares
189.38 M
Float Shares
187.67 M
Insiders
1.59%
Institutions
86.16%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
EXAS Catalyst Timeline
Dated clinical, regulatory and corporate events for Exact Sciences Corporation
Past FDA Catalysts and PDUFA Decisions
How EXAS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Exact Sciences Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every EXAS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Oncodetect® | early triple-negative breast cancer | 2026-03-17 | Pre-surgery ctDNA status following neoadjuvant therapy (NAT) was strongly associated with both pathologic complete response (pCR) and distant recurrence-free interval (dRFI).Read More | Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Baranick BrianOfficer (EVP, GM, Precision Oncology) | Grant/Award | 33,321 137,195 held | $0.00 | 03/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EXAS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 2.2 % (214.3 %) | 121.92 M | 1.20 M | 157.9% ( 735.00 K) |
EXAS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EXAS ranks across every disease it competes in
Competitive Position is a premium feature
See how EXAS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEXAS News
About Exact Sciences Corporation
Headquarters5505 ENDEAVOR LANE, MADISON, WI, 53719
Founded1995
BIOPHARMAWATCH ELITE PLUS
Trade the next EXAS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime